EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J D Ross, Bruce C Carleton

Frontiers in Pharmacology · 08.09.2023 · 14

DOI: 10.3389/fphar.2023.1257745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.09.2023. Verfasst von Angela Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of British Columbia, Vancouver, BC, Canada. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fluoropyrimidine toxicity is often due to variations in the gene ( DPYD ) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels.

Methods

A multiplex QPCR assay was locally developed to allow genotyping for six DPYD variants. The test was offered prospectively for all patients starting on fluoropyrimidines at the BC Cancer Centre in Vancouver and then across B.C., Canada as well as retrospectively for patients suspected to have had an adverse reaction to therapy. Dose adjustments were made for variant carriers. The incidence of toxicity in the first three cycles was compared between DPYD variant allele carriers and non-variant carriers. Subsequent to an initial implementation phase, this test was made available province-wide.

Results

In 9 months, 186 patients were tested and 14 were found to be heterozygous variant carriers. Fluoropyrimidine-related toxicity was higher in DPYD variant carriers. Of 127 non-variant carriers who have completed chemotherapy, 18 (14%) experienced severe (grade ≥3, Common Terminology Criteria for Adverse Events version 5.0). Of note, 22% (3 patients) of the variant carriers experienced severe toxicity even after DPYD -guided dose reductions. For one of these carriers who experienced severe thrombocytopenia within the first week, DPYD testing likely prevented lethal toxicity. In DPYD variant carriers who tolerate reduced doses, a later 25% increase led to chemotherapy discontinuation. As a result, a recommendation was made to clinicians based on available literature and expert opinion specifying that variant carriers who tolerated two cycles without toxicity can have a dose escalation of only 10%.

Conclusion

DPYD -guided dose reductions were a feasible and acceptable method of preventing severe toxicity in DPYD variant carriers. Even with dose reductions, there were variant carriers who still experienced severe fluoropyrimidine toxicity, highlighting the importance of adhering to guideline-recommended dose reductions. Following the completion of the pilot phase of this study, DPYD genotyping was made available province-wide in British Columbia.

Schlagwörter

Stichwörter der Autor:innen

DPYDadverse drug reactionsclinical implementationfluoropyrimidine toxicitypharmacogenetics

Autor:innen und Institutionen

  • Department of Experimental Medicine, University of British Columbia, Vancouver, BC, Canada.
  • BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Medical Oncology, BC Cancer, Provincial Health Services Authority, Vancouver, BC, Canada.
  • Cancer Genetics and Genomics Laboratory, BC Cancer, Provincial Health Services Authority, Vancouver, BC, Canada.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Zitieren

APA

Wu, A., Anderson, H., Hughesman, C., Young, S., Lohrisch, C., Ross, C. J. D., & Carleton, B. C. (2023). Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1257745

Vancouver

Wu A, Anderson H, Hughesman C, Young S, Lohrisch C, Ross CJD, et al. Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1257745

BibTeX
@article{Wu2023,
  author = {Wu, Angela and Anderson, Helen and Hughesman, Curtis and Young, Sean and Lohrisch, Caroline and Ross, Colin J D and Carleton, Bruce C},
  title = {Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1257745}
}
Kostenlos starten →